Medical management of thyroid cancer: a risk adapted approach

Risk adapted treatment recommendations are dependent on accurate predictions of the risk of recurrence, risk of death, and likely sites of recurrence. When combined with response to therapy assessments and secondary risk stratification during follow‐up, this risk adapted approach will allow the clinician to tailor the aggressiveness of therapy and follow up to the risk of recurrence and death in individual patients. J. Surg. Oncol. 2008;97:712–716. © 2008 Wiley‐Liss, Inc.

[1]  S. Jhiang,et al.  Differentiated thyroid cancer long-term impact of initial therapy. , 1995, Transactions of the American Clinical and Climatological Association.

[2]  R. Tuttle,et al.  Papillary thyroid cancer: monitoring and therapy. , 2007, Endocrinology and metabolism clinics of North America.

[3]  W. Taylor,et al.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. , 1987, Surgery.

[4]  J. Shah,et al.  Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. , 1995, Surgery.

[5]  D. Dean,et al.  Prognostic indicators in differentiated thyroid carcinoma. , 2000, Cancer control : journal of the Moffitt Cancer Center.

[6]  M. van Glabbeke,et al.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. , 1979, European journal of cancer.

[7]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[8]  R. Kloos,et al.  Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer , 2001 .

[9]  I. Sugitani,et al.  A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. , 2004, Surgery.

[10]  H. Gharib,et al.  AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[11]  J. Watkinson,et al.  The British Thyroid Association guidelines for the management of thyroid cancer in adults , 2004, Nuclear medicine communications.

[12]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[13]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[14]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[15]  J. Shah,et al.  Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996 , 2000, Cancer.

[16]  P. Ladenson,et al.  Prospective multicenter study of thyroid carcinoma treatment , 1998 .

[17]  J. Shah,et al.  Low-risk differentiated thyroid cancer: The need for selective treatment , 1997, Annals of Surgical Oncology.